AstraZeneca has become the latest drug firm to invest in Russian manufacturing capcity with the announcment of plans for a $150m facility in the country’s Kaluga region.
UK-based Endeavour Specialty Chemicals has launched a range of thioamide intermediates, citing growing evidence of their potential role in development of new cancer treatments.
US Heparin maker Scientific Protein Laboratories (SPL) says it has resolved “many of the issues” addressed in the US Food and Drug Administration (FDA) warning letter it received late last month.
Ugandan drugmaker Quality Chemicals Industries (QCI) will invest $80m in manufacturing operations to boost capacity for the production of generic AIDS and malaria drugs.
Hospira has confirmed it will no longer make Pentothal - an anaesthetic used in lethal injections – as the company “never condoned” its use in executions.
The US FDA has suggested pharmaceutical firms use a maximum bead size of 2.0mm for modified-release drugs formulated for “sprinkle” delivery to avoid problems resulting from inadvertent chewing.
ShangPharma has opened a multi-purpose pharmaceutical development cGMP manufacturing facility in Fengxian, China, and started operations on the initial phase of production.
Bristol-Myers Squibb has recalled 64m tablets of its Avalide blood pressure drug in the US and Puerto Rico over fears it has the potential for reduced efficacy.
The European Medicines Agency (EMA) has highlighted the quality APIs manufactured outside the EU as an area of concern in the draft 2015 road map it unveiled this week.
Regulations and enforcement were big topics yet again in 2010. in-PharmaTechnologist presents five of our most read on the topics, covering starting material quality and overseas inspections.
Big pharma continued to cut in 2010, closing plants and laying off staff in an attempt to cut costs and adjust post-merger. in-PharmaTechnologist presents a round up of five of the most read in 2010.
Bayer HealthCare is investing €35m ($47m) in a new centre for the biotechnological production of ‘innovative’ pharmaceuticals to be used in clinical trials.
Pharma should forget about ‘the next blockbuster drug’ and invest more money creating novel drug delivery systems with emerging developers to enhance product value and efficacy, say researchers.
Vical has published a review of Vaxfectin data showing the adjuvant boosts the immune response of DNA-based vaccines against cancer and a range of pathogens.
Drafting ICH M7 guidance on genotoxic impurities will require a lot of work from industry and regulators but has the potential to resolve a number of issues.
WikiLeaks has published a list of overseas biopharmaceutical facilities considered vital to US national security as part of its release of leaked diplomatic cables.
DSM Special Products and DSM IP Assets look set to be sold to equity investor Sun Capital as the European Commission has given competition approval with no strings attached.
Narrowly defined pharma self-interest and lack of coordinated political effort means, despite the best effort of some, the problem of counterfeiting may be worsening.
Pfizer has welcomed Government commitments to keep Ireland’s 12.5 per cent corporation tax rate in face of recent EU pressure to increase it as a condition of the €85bn 7-year IMF bailout.
Aluminium lakes and in-liner packaging can, in some cases, be used to control reactive components in excipients and therefore overcome drug product instability.
Camlin Fine Chemicals has been given the green light from its board of directors to acquire an unnamed Italian fine chemicals manufacturer and form a subsidiary company to help boost its presence in the Middle East.
Drug manufacturers do not pay enough attention to the colour of their drugs, according to researchers examining the importance of aesthetics in pharmaceutical over-the-counter (OTC) products.